| Literature DB >> 30778280 |
Paula H Heikkinen1, Friedemann Pulvermüller2, Jyrki P Mäkelä3, Risto J Ilmoniemi4, Pantelis Lioumis5, Teija Kujala6, Riitta-Leena Manninen3, Antti Ahvenainen3, Anu Klippi1.
Abstract
Neuromodulation technologies, such as transcranial magnetic stimulation (TMS), are promising tools for neurorehabilitation, aphasia therapy included, but not yet in common clinical use. Combined with behavioral techniques, in particular treatment-efficient Intensive Language-Action Therapy (ILAT, previously CIAT or CILT), TMS could substantially amplify the beneficial effect of such behavioral therapy alone (Thiel et al., 2013; Martin et al., 2014; Mendoza et al., 2016; Kapoor, 2017). In this randomized study of 17 subjects with post-stroke aphasia in the chronic stage, we studied the combined effect of ILAT and 1-Hz placebo-controlled navigated repetitive TMS (rTMS) to the right-hemispheric inferior frontal cortex-that is, to the anterior part of the non-dominant hemisphere's homolog Broca's area (pars triangularis). Patients were randomized to groups A and B. Patients in group A received a 2-week period of rTMS during naming training where they named pictures displayed on the screen once every 10 s, followed by 2 weeks of rTMS and naming combined with ILAT. Patients in group B received the same behavioral therapy but TMS was replaced by sham stimulation. The primary outcome measures for changes in language performance were the Western Aphasia Battery's aphasia quotient AQ; the secondary outcome measures were the Boston naming test (BNT) and the Action naming test (Action BNT, ANT). All subjects completed the study. At baseline, no statistically significant group differences were discovered for age, post-stroke time or diagnosis. ILAT was associated with significant improvement across groups, as documented by both primary and secondary outcome measures. No significant effect of rTMS could be documented. Our results agree with previous results proving ILAT's ability to improve language in patients with chronic aphasia. In contrast with earlier claims, however, a beneficial effect of rTMS in chronic post-stroke aphasia rehabilitation was not detected in this study. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03629665.Entities:
Keywords: ILAT; chronic aphasia; efficacy; language rehabilitation; rTMS; randomized controlled trial (RCT)
Year: 2019 PMID: 30778280 PMCID: PMC6369187 DOI: 10.3389/fnins.2018.01036
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1The flow of participants in the randomized, placebo-controlled study.
Clinical and sociodemographic information about the patient sample.
| 1 | M | 53 | 2.9 | Ischemic stroke | Conduction (70.0) | TP |
| 2 | M | 49 | 5.1 | Ischemic stroke | Anomic (74.0) | FTP, BG, INS |
| 3 | M | 53 | 2.8 | Ischemic stroke | Transcortical motor (55.8) | FTP, BG, INS |
| 4 | F | 62 | 2.8 | Ischemic stroke | Conduction (61.7) | FTP, BG, PVWM, IC INS |
| 5 | M | 52 | 2.0 | Ischemic stroke | Broca (37.0) | FTP |
| 6 | M | 72 | 4.4 | Ischemic stroke | Broca (52.5) | FP, INS, PVWM, BG, IC |
| 7 | M | 37 | 1.0 | Ischemic stroke | Conduction (72.2) | TP |
| 8 | F | 58 | 3.6 | Hemorrhage | Anomic (74.1) | BG, INS, PVWM, IC |
| 9 | M | 47 | 1.4 | Hemorrhage | Anomic (71.1) | BG, PVWM, IC |
| 10 | M | 59 | 4.6 | Hemorrhage | Conduction (68.8) | TP |
| 11 | M | 69 | 2.5 | Ischemic stroke | Broca (71.0) | FTP, INS |
| 12 | M | 50 | 2.7 | Ischemic stroke | Anomic (87.0) | TP |
| 13 | F | 54 | 8.2 | Ischemic stroke | Anomic (80.7) | BG, PVWM, INS |
| 14 | F | 63 | 4.3 | Ischemic stroke | Anomic (87.8) | FP |
| 15 | M | 68 | 1.3 | Ischemic stroke | Anomic (77.6) | FP, PVWM, BG |
| 16 | M | 54 | 2.0 | Ischemic stroke | Conduction (58.7) | FTP |
| 17 | M | 69 | 6.8 | Ischemic stroke | Anomic (90.5) | INS, PVWM |
All lesions were in the left hemisphere. TP, temporoparietal; FTP, frontotemporoparietal, FP, frontoparietal; BG, basal ganglia; PVWM, periventricular white matter; INS, insula; IC, internal capsule.
Baseline Characteristics of the two patient groups undergoing treatment.
| Mean age (range), year | 54 (37–73) (sd:9.94) | 61 (50–69) (sd:7.47) | 0.093/0.189 |
| Male, | 7 (77%) | 6 (75%) | |
| Right handedness, | 9 (100%) | 8 (100%) | |
| Mean education, year | 12 | 13 | |
| Mean time since onset of aphasia (range), months | 34 (11–60) (sd:490.77) | 48 (15–96) (sd:881.69) | 0.541/1.000 |
| Mean WAB-AQ (range) (max. = 100) | 63.2 (37–74.1) (sd:12.66) | 77.8 (58.7–90.5) (sd:11.00) | 0.046*/0.152 |
| Mean BNT (max. = 60) | 29 (4–53) (sd:14.76) | 41 (16–58) (sd:16.24) | 0.118 |
| Mean ANT (max. = 60) | 26 (4–49) (sd:13.12) | 52 (5–54) (sd:18.30) | 0.262 |
The right column indicates significance of differences between groups for the full groups and the matched groups after removal of two outliers.
Sd, standard deviation. *Statistically significant p-value.
Figure 2Study design.
Figure 3Average aphasia severity for the entire group of 17 post-stroke aphasia patients across the 4 assessments. The panel on the left shows WAB-AQ scores at timepoints T1 (baseline), T2 (after rTMS/placebo + low-intensity naming therapy), T3 (after rTMS/placebo + ILAT) and T4 (3 m follow-up). Error bars indicate standard errors of the mean. The right panel shows the changes of WAB-AQ scores across the first (T1–T2) and second therapy intervals (T2–T3) and the 3 months after therapy (T3–T4). Asterisks (*) index significant effect.